Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Ocugen Inc
(NQ:
OCGN
)
0.9357
-0.0143 (-1.51%)
Streaming Delayed Price
Updated: 9:53 AM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ocugen Inc
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
32
33
Next >
30 Stocks Moving In Tuesday's Mid-Day Session
October 12, 2021
Gainers ESS Tech Inc (NYSE: GWH) shares jumped 96.4% to $20.46. ESS Inc, the Bill Gates-backed battery maker went public on the New York Stock Exchange on Monday after...
Via
Benzinga
OCGN Stock: One Big Reason Ocugen Is Powering Higher Today
October 12, 2021
OCGN stock is making its investors quite happy this morning and prompting many more to pile in. The company is receiving crucial approval.
Via
InvestorPlace
Exposures
COVID-19
Why Ocugen Stock Is on Fire Today
October 12, 2021
A positive regulatory development in India is sending the biotech's shares higher today.
Via
The Motley Fool
Exposures
COVID-19
Why Ocugen's Stock Is Trading Higher Today
October 12, 2021
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after the Indian government approved Bharat Biotech's COVID-19 vaccine, Covaxin, for children between the age of...
Via
Benzinga
Exposures
COVID-19
Ocugen Will Have Value If Its Covid Vaccine Can Get Approved
October 12, 2021
OCGN stock could be at a full value today given revenue prospects but could still rise if its Covaxin vaccine gains approval outside India.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 12, 2021
Gainers Viridian Therapeutics (NASDAQ:VRDN) stock rose 22.49% to $19.17 during Tuesday's pre-market session. The company's market cap stands at $331.8 million. Inhibrx (...
Via
Benzinga
15 Stocks Moving in Tuesday's Pre-Market Session
October 12, 2021
Gainers Quanterix Corporation (NASDAQ: QTRX) shares rose 17.6% to $48.55 in pre-market trading after the company announced its Simoa phospho-Tau 181 blood test has been granted...
Via
Benzinga
Don’t Buy Too Much Into the WHO Hype Surrounding Ocugen Stock
October 12, 2021
The latest buzz around Covaxin does little to improve the prospects of OCGN stock, so buying it for this reason doesn't make much sense.
Via
InvestorPlace
Exposures
COVID-19
Why Did Ocugen Stock Skyrocket On Monday?
October 12, 2021
Shares of biopharmaceutical company Ocugen Inc. (NASDAQ: OCGN) surged almost 8.8% in Monday’s regular trading session and also gained 11.4% in the after-hours session. What...
Via
Benzinga
OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN
October 08, 2021
From
Kahn Swick & Foti, LLC
Via
Business Wire
WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources
October 05, 2021
The World Health Organization said a decision on the Emergency Use Listing (EUL) of India's COVID-19 vaccine, Covaxin, will be finalized next week. Ocugen Inc (...
Via
Benzinga
Exposures
COVID-19
Ocugen Bulls Are Overlooking Its FDA Approval Hurdles
October 05, 2021
The FDA seems highly unlikely to approve the Covaxin vaccine, making OCGN stock an excellent name to short going forward.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
OCGN Stock: 2 Huge Reasons Ocugen Stock Is Shooting Higher Today
October 05, 2021
OCGN stock is surging on some big news. The World Health Organization could give the company the go-ahead on its Covid-19 vaccine very soon.
Via
InvestorPlace
Exposures
COVID-19
Why Ocugen Shares Are Trading Higher Today
October 05, 2021
Ocugen Inc (NASDAQ: OCGN) is trading higher Tuesday after a company 8-K showed it entered into a Development and Commercial Supply Agreement with Bharat Biotech pursuant to...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 05, 2021
Gainers Ocugen (NASDAQ:OCGN) shares moved upwards by 11.11% to $7.5 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.4...
Via
Benzinga
WHO Approval Won’t Move Ocugen Stock Very Much Over the Long Term
October 05, 2021
The WHO's nod of approval wont be fruitful to OCGN stock in blowing past the regulatory hurdles in the North American Covid 19 vaccine market.
Via
InvestorPlace
Exposures
COVID-19
16 Stocks Moving in Tuesday's Pre-Market Session
October 05, 2021
Gainers Marine Petroleum Trust (NASDAQ: MARPS) rose 25.4% to $6.29 in pre-market trading after gaining 8% on Monday. Agrify Corporation. (NASDAQ: AGFY) rose 17.8% to $21.76 in...
Via
Benzinga
WHO To Decide On EUL Of Ocugen-Partnered COVID-19 Vaccine Today
October 05, 2021
An expert panel of the World Health Organization (WHO) will decide on the emergency use listing (EUL) authorization of Covaxin today. Covaxin is India's indigenously-...
Via
Benzinga
Exposures
COVID-19
Ocugen Stock Just Needs a Catalyst to Break Free
October 04, 2021
OCGN stock holders should be patient as the World Health Organization's potential approval of an important vaccine could happen soon.
Via
InvestorPlace
Exposures
COVID-19
It’s Time To Drop Ocugen Stock While You Still Can
October 04, 2021
Hope is one thing, but for OCGN stock investors expecting regulators or other bulls to come to the rescue, things are starting to look gloomy.
Via
InvestorPlace
Ocugen Still Lacks a Path to U.S. Profits
September 29, 2021
Ocugen still lacks a proper catalyst and nothing has changed for it. As a result, investors should avoid OCGN stock.
Via
InvestorPlace
Exposures
COVID-19
Product Safety
Ocugen, Inc. (NASDAQ:OCGN) Long Term Investor Alert: Investigation of Potential Wrongdoing
September 28, 2021
San Diego, CA -- (SBWIRE) -- 09/28/2021 -- Certain directors of Ocugen, Inc are under investigation concerning potential breaches of fiduciary duties by certain directors of Ocugen, Inc.
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources
September 27, 2021
The World Health Organization (WHO) has further delayed the emergency use authorization (EUA) for Covaxin, a COVID-19 vaccine developed in India. Ocugen Inc (NASDAQ:...
Via
Benzinga
Exposures
COVID-19
Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin?
September 24, 2021
An anticipated emergency use listing for the vaccine won't help Ocugen.
Via
The Motley Fool
Exposures
COVID-19
Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report
September 21, 2021
India-based Bharat Biotech has completed the Phase 2 and 3 trials of COVID-19 vaccine, Covaxin, for use in 2 to 18 years. Ocugen Inc (NASDAQ: OCGN...
Via
Benzinga
Exposures
COVID-19
It’s OK to Sell the News on Ocugen and Covaxin
September 20, 2021
OCGN stock jumped when Covaxin received WHO approval. But with two major obstacles in the way of U,S. approval, you should sell the news.
Via
InvestorPlace
Could This News Spark a Turnaround for Ocugen?
September 19, 2021
Ocugen shares soared more than 700% early in the year. They've since lost half of the gain.
Via
The Motley Fool
Exposures
COVID-19
Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising
September 17, 2021
Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.
Via
The Motley Fool
Exposures
COVID-19
I’d Take Nio Stock’s 12-Month Double Despite Falling Below $50
September 17, 2021
A $10,000 investment in NIO stock a year ago is worth more than $20,000 today. From here, under $40 remains a great entry point if you want to make money over the long haul.
Via
InvestorPlace
Topics
Electric Vehicles
Exposures
Electric Vehicles
WHO Approval Should Get Ocugen Stock Over the $15 Barrier
September 16, 2021
Sharp up-and-down moves in OCGN stock shouldn't scare investors away, as a regulator's nod for Covaxin should put the stock back on track.
Via
InvestorPlace
< Previous
1
2
...
18
19
20
21
22
23
24
25
26
...
32
33
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.